Our History and Mission
The highlights
Virolab has conducted research and development for the invention of a gene therapy for HPV elimination, with completed and current medical protocols and multiple scientific publications. Has a group of professionals who have supported it in converting scientific ideas into a project of global dimensions.
VIROLAB developed the only vaccine in the world with curative effects that eliminates HPV with an efficiency greater than 90%, thus eliminating pre and cancerous lesions in the cervix of infected patients.
Our potential market is 300 million women who already have cervical lesions worldwide; (500,000 develop cervical cancer each year, and half of them will die) or, put another way, 70% of the world's total population, who, according to the WHO, have some type of HPV and do not necessarily present lesions, are eligible for treatment with the vaccine (Virolab Gene Therapy).
Virolab has no competitors when it comes to the GAB-1 therapeutic vaccine, as this therapeutic vaccine is unique worldwide, and there is no other similar vaccine with the same properties and characteristics.
Solutions to Public Health Problems in the World
At VIROLAB, we are dedicated to providing innovative solutions for the diagnosis and treatment of viral diseases. Our focus is on developing therapeutic vaccines against lesions caused by human papillomaviruses (HPV) and cancers such as melanomas and breast cancer.
Join Our Mission
We are always looking for partners to innovate in the field of biotechnology. Together, we can advance viral health and global well-being.
SCIENTIFIC ARTICLES
-Mar-Salas H, Rosales R. Giant condyloma acuminatum covering the vulva, edges of the labia minora and majora and anus was successfully eliminated with MVA E2 recombinant virus therapeutic vaccination. Annals of case Reports. 2022 Dec; 7 (6):1097. Doi: 10.29011/2574-7754.101097.
-Cabo Beltran OR, Rosales Ledezma R. MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis. Head Neck. 2019 Mar; 41 (3): 657-665. doi: 10.1002/hed.25477. PMID: 30605254.
-Rosales R, López-Contreras M, Rosales C, Magallanes-Molina JR, Gonzalez-Vergara R, Arroyo-Cazarez JM, Ricardez-Arenas A, Del Follo-Valencia A, Padilla-Arriaga S, Guerrero MV, Pirez MA, Arellano-Fiore C, Villarreal F. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum. Gene Ther. 2014 Dec; 25 (12): 1035-1049. doi: 10.1089/hum.2014.024. PMID: 25275724.
-Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. World J. Clin. Oncol. 2014 Dec 10; 5 (5): 1002-1019. doi: 10.5306/wjco.v5.i5.1002. PMID: 25493236
-Albarran y Carvajal A, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Díaz Estrada I, Mendez Fuentez E, López Contreras M, Andrade-Manzano A, Padilla S, Varela AR, Rosales R. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs. 2007; 21 (1): 47-59. doi: 10.2165/00063030-200721010-00006. PMID: 17263589.
-García-Hernández E, González-Sánchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzmán CC, Jiménez R, Reyes L, Morosoli G, Verde ML, Rosales R. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer. Gene Ther. 2006 Jun; 13 (6): 592-597. doi: 10.1038/sj.cgt.7700937. PMID: 16456551.
-Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. 2004 May; 15 (5): 421-431. doi: 10.1089/10430340460745757. PMID: 15144573.
-Roque-Reséndiz JL, Rosales R, Herion P. MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis. Parasitology. 2004 Apr; 128 (Pt 4): 397-405. doi: 10.1017/s0031182003004761. PMID: 15151145.
-Rincón-Arano H, Rosales R, Mora N, Rodriguez-Castañeda A, Rosales C. R-Ras promotes tumor growth of cervical epithelial cells. Cancer. 2003 Feb 1; 97 (3): 575-585. doi: 10.1002/cncr.11093. PMID: 12548599.
-Corona Gutierrez CM, Tinoco A, López Contreras M, Navarro T, Calzado P, Vargas L, Reyes L, Posternak R, Rosales R. Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum. Gene Ther. 2002 Jun 10; 13 (9): 1127-1140. doi: 10.1089/104303402753812520. PMID: 12067445.
-García-García E, Rosales R, Rosales C. Phosphatidylinositol 3-kinase and extracellular signal-regulated kinase are recruited for Fc receptor-mediated phagocytosis during monocyte-to-macrophage differentiation. J. Leukoc. Biol. 2002 Jul; 72 (1): 107-114. doi: 10.1189/jlb.72.1.107. PMID: 12101269.
-Rosales R, López-Contreras M, Cortes RR. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlationwith presence of papillomavirus DNA. J. Med. Virol. 2001 Dec; 65 (4): 736-744. doi: 10.1002/jmv.2098. PMID: 11745939.
-Rosales C, Graham VV, Rosas GA, Merchant H, Rosales R. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol. Immunother. 2000 Sep; 49 (7): 347-360. doi: 10.1007/s002620000125. PMID: 10999461.
-Valdez Graham V, Sutter G, José MV, García-Carranca A, Erfle V, Moreno Mendoza N, Merchant H, Rosales R. Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer. 2000 Apr 1; 88 (7): 1650-1662. doi: 10.1002/(sici)1097-0142(20000401)88:7<1650::aid-cncr20>3.0.co;2-l. PMID: 10738224.